Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph E Dinchuk

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Immunology Letters|February 26, 2003
COX-3: in the wrong frame in mindJoseph E Dinchuk, Richard Q Liu, James M Trzaskos
Endocrinology|July 9, 2010
Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807Joseph E Dinchuk, Carolyn Cao, Fei Huang, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
Antisense oligonucleotides selectively regulate aspartyl beta-hydroxylase and its truncated protein isoform in vitro but distribute poorly into A549 tumors in vivoSiew Peng Ho, Michael S Scully, Candice M Krauthauser, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 17, 2009
Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 inductionSean Kim, Joseph E Dinchuk, Monique N Anthony, et al.
The Prostate|September 30, 2010
Drug safety is a barrier to the discovery and development of new androgen receptor antagonistsWilliam R Foster, Bruce D Car, Hong Shi, et al.
Plos One|November 1, 2014
P2Y6 receptor potentiates pro-inflammatory responses in macrophages and exhibits differential roles in atherosclerotic lesion developmentRicardo A Garcia, Mujing Yan, Debra Search, et al.
The Journal of Biological Chemistry|January 5, 2002
Absence of post-translational aspartyl beta-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasiaJoseph E Dinchuk, Richard J Focht, Jennifer A Kelley, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Immunology Letters|February 26, 2003
COX-3: in the wrong frame in mindJoseph E Dinchuk, Richard Q Liu, James M Trzaskos
Endocrinology|July 9, 2010
Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807Joseph E Dinchuk, Carolyn Cao, Fei Huang, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
Antisense oligonucleotides selectively regulate aspartyl beta-hydroxylase and its truncated protein isoform in vitro but distribute poorly into A549 tumors in vivoSiew Peng Ho, Michael S Scully, Candice M Krauthauser, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 17, 2009
Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 inductionSean Kim, Joseph E Dinchuk, Monique N Anthony, et al.
The Prostate|September 30, 2010
Drug safety is a barrier to the discovery and development of new androgen receptor antagonistsWilliam R Foster, Bruce D Car, Hong Shi, et al.
Plos One|November 1, 2014
P2Y6 receptor potentiates pro-inflammatory responses in macrophages and exhibits differential roles in atherosclerotic lesion developmentRicardo A Garcia, Mujing Yan, Debra Search, et al.
The Journal of Biological Chemistry|January 5, 2002
Absence of post-translational aspartyl beta-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasiaJoseph E Dinchuk, Richard J Focht, Jennifer A Kelley, et al.
Pageof 1